Usana Health Sciences, Inc., a Utah-based nutritional, skincare and dietary products manufacturer, indicates in its recently filed 8-K that it has substantially completed an internal investigation into whether the expense reimbursement policy and other practices at its Chinese affiliate, BabyCare Ltd., were compliant with the Foreign Corrupt Practices Act. The company reports that it is cooperating with the DOJ and the SEC in their investigations of the matter.
February 5, 2019
DOJ and SEC investigating nutritional supplement maker for possible FCPA violations
Related by Topic
New Post
Hit Them Where It Hurts (The Pocketbook): DOJ’s Most Recent Corporate Enforcement Guidance
March 9, 2023
Insight